RSS
monotherapy
Once-daily monotherapy is not inferior to twice-daily treatment in epilepsy, notes study
Data, recently published in the journal Epilepsia, has demonstrated once-daily monotherapy, Zebinix (esclicarbazeptine acetate), is non-inferior to twice-daily controlled released carbamazepine in the treatment of newly diagnosed focal epilepsy Read more
EC approves monotherapy for women with recurrent ovarian cancer
Biopharmaceutical company, Tesaro, has revealed that the European Commission has approved its monotherapy for the maintenance treatment of women with recurrent ovarian cancer. Read more
